BMY Downgraded by Leerink Partners -- Price Target Lowered to $5
Leerink Partners downgraded Bristol-Myers Squibb (BMY) from Outperform to Market Perform, lowering its price target from $73 to $59. The company's stock is currently trading at $61.15, which is 7.9% above its GF Value™ of $56.66, indicating overvaluation. BMY has a GF Score™ of 72/100, with strengths in profitability but weaknesses in momentum. Insider selling activity totaled $437,248 over the past three months.
How this was made
The 30-second read
Why it matters
The downgrade could prompt short‑term sell‑offs, but the company's solid profitability may support a rebound if earnings beat expectations.
Market read
Analyst rating changes are a primary driver of short‑term price moves for large‑cap stocks like BMY.
What to watch
Insider selling activity and valuation metrics suggest underlying concerns not fully captured by the rating change.
Background
BMY is a $125 B market‑cap biopharma with products like Opdivo; recent analyst sentiment has been mixed.
Ticker impact
Leerink Partners downgraded Bristol‑Myers Squibb to Market Perform and cut the price target to $59, a fresh analyst action that can affect the stock price.
likely downward pressure as investors price in the lower target
Analyst rating change and target reduction are direct catalysts that typically move the stock in the short term.
Market effects
May weigh on the broader pharma/biotech sector as peers could face similar scrutiny.
Limited to U.S. markets where BMY is listed.
Minimal global impact beyond investors tracking large-cap pharma stocks.
Counterpoint
Some investors may view the downgrade as an overreaction given BMY's strong cash flow and pipeline.
Key entities
- analyst firmLeerink Partners
Provided the downgrade and new price target.
- analystDavid Risinger
Cited outlook adjustments as reason for downgrade.
